Ionis Pharmaceuticals Inc (NASDAQ: IONS) on Tuesday, soared 34.84% from the previous trading day, before settling in for the closing price of $42.63. Within the past 52 weeks, IONS’s price has moved between $23.95 and $50.43.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 14.67%. With a float of $158.08 million, this company’s outstanding shares have now reached $159.20 million.
Ionis Pharmaceuticals Inc (IONS) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Ionis Pharmaceuticals Inc is 0.82%, while institutional ownership is 106.68%. The most recent insider transaction that took place on Sep 02 ’25, was worth 1,931,664. Before that another transaction happened on Sep 02 ’25, when Company’s Officer proposed sale 11,130 for $49.67, making the entire transaction worth $552,865.
Ionis Pharmaceuticals Inc (IONS) Recent Fiscal highlights
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.72 earnings per share (EPS) for the period topping the consensus outlook (set at -0.98) by 0.26. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.06 per share during the current fiscal year.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) Trading Performance Indicators
Ionis Pharmaceuticals Inc (IONS) is currently performing well based on its current performance indicators. A quick ratio of 2.86 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.85, a number that is poised to hit -1.23 in the next quarter and is forecasted to reach -3.06 in one year’s time.
Technical Analysis of Ionis Pharmaceuticals Inc (IONS)
Looking closely at Ionis Pharmaceuticals Inc (NASDAQ: IONS), its last 5-days average volume was 4.65 million, which is a jump from its year-to-date volume of 1.85 million. As of the previous 9 days, the stock’s Stochastic %D was 51.32%.
During the past 100 days, Ionis Pharmaceuticals Inc’s (IONS) raw stochastic average was set at 98.73%, which indicates a significant increase from 97.37% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.79 in the past 14 days, which was higher than the 1.34 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $42.25, while its 200-day Moving Average is $35.50. However, in the short run, Ionis Pharmaceuticals Inc’s stock first resistance to watch stands at $60.56. Second resistance stands at $63.64. The third major resistance level sits at $69.35. If the price goes on to break the first support level at $51.77, it is likely to go to the next support level at $46.06. Now, if the price goes above the second support level, the third support stands at $42.98.
